drugset / Trial / NCT00252798
ZD1839 (Iressa™) and Concurrent Chemo-Radiation in Patients With Locally Advanced Non Small Cell Lung Cancer
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The primary objective of the trial is to determine the Maximum tolerated dose, if any, of the combination of daily ZD1839 250 mg with carboplatin AUC 2 and 60 Gray (Gy) irradiation and up to 45 mg/m2 paclitaxel.
Timeline
- Start
- 2002-07
- Primary completion
- —
- Completion
- 2005-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Carboplatin | Small molecule | — | — |
| Subject | Gefitinib | Small molecule | 250 mg | — |
| Subject | Paclitaxel | Small molecule | 45 mg/m2 | — |